Abstract | BACKGROUND: METHOD: Twenty HIV-infected outpatients with MDD according to DSM-IV criteria were treated with reboxetine, 8 mg/day, for 12 weeks within an open trial design. Outcome measures included the Montgomery-Asberg Depression Rating Scale (MADRS) and a side effect profile. Data were gathered from July 2000 to March 2001. RESULTS: Seventy-five percent of patients (N = 15) completed the trial. All patients who completed the trial had an improvement equal to or higher than a 50% reduction in their MADRS scores at endpoint. The most frequent adverse effects were insomnia, sweating, and shivering. CONCLUSION: Within this open trial, reboxetine was found to be effective in reducing depressive symptoms in HIV illness. The rate of dropout (25%) suggests that reboxetine may be well tolerated in this population.
|
Authors | Adriana S Carvalhal, Paulo Belmonte de Abreu, Alessandra Spode, Joel Correa, Flavio Kapczinski |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 64
Issue 4
Pg. 421-4
(Apr 2003)
ISSN: 0160-6689 [Print] United States |
PMID | 12716244
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic Uptake Inhibitors
- Antidepressive Agents
- Morpholines
- Reboxetine
|
Topics |
- Adolescent
- Adrenergic Uptake Inhibitors
(adverse effects, therapeutic use)
- Adult
- Ambulatory Care
- Antidepressive Agents
(adverse effects, therapeutic use)
- Comorbidity
- Depressive Disorder
(diagnosis, drug therapy, epidemiology)
- Female
- HIV Seropositivity
(epidemiology)
- Humans
- Hyperhidrosis
(chemically induced)
- Male
- Middle Aged
- Morpholines
(adverse effects, therapeutic use)
- Nausea
(chemically induced)
- Psychiatric Status Rating Scales
- Reboxetine
- Sleep Initiation and Maintenance Disorders
(chemically induced)
- Treatment Outcome
|